Skip to main page content

Cutting Edge Research in Oculoplastics

My Session Status

Talk | Exposé
1:30 PM, Friday 10 Jun 2022 (1 hour 30 minutes)
Break in the Exhibition Hall    03:00 PM to 03:45 PM (45 minutes)

Learning Objectives:

At the end of this session participants will be able to:

• Integrate new research techniques and ideas in managing Oculoplastics conditions.


CanMeds Roles: Medical Expert, Collaborator

Sub Sessions

1:30 PM - 1:37 PM | 7 minutes

Authors: Kevin Hodgson, André S. Pollmann, Kathryn McFadden, Ahsen Hussain.Author Disclosure Block: K. Hodgson: None. A.S. Pollmann: None. K. McFadden: None. A. Hussain:None.Abstract Body:Purpose: To present the clinical signs, diagnosis, treatment, and follow-up of a patient with a novel presentation of aberrant lacrimal gland ductules.Study Design: Descriptive ...

1:37 PM - 1:44 PM | 7 minutes

Authors: David Plemel, Ezekiel Weis, Karim Punja, Michael Ashenhurst, Andrzej Kulaga. Author Disclosure Block: D. Plemel: None. E. Weis: None. K. Punja: Membership on advisory boards or speakers’ bureaus; Name of for-profit or not-for-profit organization(s); Alcon Canada Inc, Allergan Inc, Clarion Medical Technologies. Membership on advisory boards or speakers’ bureaus; Description of relationship(s); Consultant / Advisor. M. Ashenhurst: None. ...

1:44 PM - 1:51 PM | 7 minutes

Authors: Helya Aghazadeh, Audrey Chan. Author Disclosure Block: H. Aghazadeh: None. A. Chan: None.Abstract Body:Purpose: To investigate the role and reliability of apraclonidine (brand name Iopidine) eye drops in assessment of ptosis and surgical planning for ptosis repair.Study Design: This study is designed as a retrospective chart review.Methods: A ret...

1:51 PM - 2:02 PM | 11 minutes
2:02 PM - 2:09 PM | 7 minutes

Authors: Ryan Eidsness, Malshi Kurunatilake, Mussawar Iqbal. University of Saskatchewan.Author Disclosure Block: R. Eidsness: None. M. Kurunatilake: None. M. Iqbal: NoneAbstract Body:Purpose: Discuss a case of advanced Squamous cell carcinoma (SCC) involving the eyelid, conjunctiva, and orbit that responded to Cemiplimab (Libtayo)Study Design: Study design: Case Study...

2:09 PM - 2:18 PM | 9 minutes

Authors: Jobanpreet Dhillon, Nishaant Bhambra, Daniel Q. Li, Sabrina Bergeron, Georges Shenouda, Miguel N. Burnier, Bryan P. Arthurs, Christian El-HadadAuthor Disclosure Block: *to be filled out by COS staff based on disclosure formTitle: Cemiplimab as Immunotherapy for Locally Advanced Squamous Cell Carcinoma of the EyeAbstract Body: Click or tap here to enter text.

2:25 PM - 2:35 PM | 10 minutes
2:35 PM - 2:42 PM | 7 minutes

Authors: Khaldon Abbas, Stuti M. Tanya, Bonnie He, Edsel Ing.Author Disclosure Block: K. Abbas: None. S.M. Tanya: None. B. He: None. E. Ing: None.Abstract Body:Purpose: The hazard associated with percutaneous sharps injuries (PSI) has encouraged behaviour change and the use of safety-engineered surgical sharps. The purpose of this study was to provide a comprehensive review of PSI and the benef...

2:42 PM - 2:49 PM | 7 minutes

Authors: Georges Nassrallah, Ramez Borbara, Blake Murphy, Asim Ali, Navdeep Nijhawan.Author Disclosure Block: G. Nassrallah: None. R. Borbara: None. B. Murphy: None. A. Ali: Any direct financial payments including receipt of honoraria; Name of for-profit or not-for-profit organization(s); Santen. Any direct financial payments including receipt of honoraria; Description of relationship(s); Consultant. Funded grants or clinical trials; Name of for-pro...

2:49 PM - 3:00 PM | 11 minutes

My Session Status

Send Feedback

Session detail
Allows attendees to send short textual feedback to the organizer for a session. This is only sent to the organizer and not the speakers.
To respect data privacy rules, this option only displays profiles of attendees who have chosen to share their profile information publicly.

Changes here will affect all session detail pages